drugset / Trial / NCT04020575
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
Phase 1
Recruiting
69 enrolled
Minerva Biotechnologies Corporation
City of Hope Medical Center · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\*).
Timeline
- Start
- 2020-01-15
- Primary completion
- 2025-01
- Completion
- 2035-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | huMNC2-CAR22 | Cell therapy | — | — |
| Subject | huMNC2-CAR44 | Cell therapy | — | — |